Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $67

Benzinga · 2d ago
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $67.